Dr. Junjian Liu has been Vice President and Head of Drug Discovery at Innovent Biologics from 2015, leading discovery of novel antibody therapeutics and development of R&D pipeline. Prior to Innovent, he was Executive Director of Biologics Discovery at WuXi Biologics, responsible for building discovery pipeline portfolio and developing novel antibody platforms, especially bispecific antibody technology. From 2006 to 2014, he had been a group leader at Abbott/AbbVie Bioresearch Center focusing on discovery project execution, molecular biology and engineering of novel antibody formats.

Dr. Liu held a Ph.D. degree in cell biology from Peking University. Before taking an industrial career, he received a postdoc training at Northwest University.

During his career, Dr. Liu had supervised/led more than 10 drug discovery projects and developed several novel antibody platforms. He also authored more than 10 research articles, 7 granted patents and more than 20 patent applications.

Drug Discovery; Antibody therapeuticsl; Biologics Discovery; Ophthalmology.